68Ga-PSMA-11 PET/CT在前列腺癌初诊与复发患者中对放疗管理的影响:121例分析
研究分析121例前列腺癌患者(50例初诊未治疗、11例术后PSA持续、60例根治后PSA复发)行68Ga-PSMA-11 PET/CT及常规影像,比较TNM分期与放疗管理变化。总体TNM分期改变49例(40.5%)、放疗管理改变62例(51.2%);初诊组分别改变26.0%与44.0%,PSA持续或复发组分别改变50.7%与56.3%。作者认为68Ga-PSMA-11 PET/CT可能成为检测前列腺癌病灶不可或缺的工具,并似乎非常有助于根据个体疾病分布制定个性化放疗管理。
要点
- 121例前列腺癌患者中,68Ga-PSMA-11 PET/CT使49例(40.5%)TNM分期改变、62例(51.2%)放疗管理改变。
- 初诊未治疗患者TNM分期改变26.0%、放疗计划改变44.0%。
- PSA持续或复发患者TNM分期改变50.7%、放疗管理改变56.3%。
核心结论
- 68Ga-PSMA-11 PET/CT可能不久将成为检测初诊未治疗及复发或PSA持续前列腺癌患者病灶不可或缺的工具。
- 68Ga-PSMA-11 PET/CT似乎非常有助于根据个体疾病分布制定个性化放疗管理。
研究设计与样本
- 本研究分析121例前列腺癌患者,均行68Ga-PSMA-11 PET/CT及常规影像。
- 50例为初诊未治疗,11例为术后不久PSA持续,60例为根治性治疗后PSA复发。
- 比较68Ga-PSMA-11 PET/CT后TNM分期与放疗管理相对常规影像的变化。
主要发现
- 总体TNM分期改变49例(40.5%),放疗管理改变62例(51.2%)。
- 初诊未治疗患者TNM分期改变26.0%,放疗计划改变44.0%。
- PSA持续或复发患者TNM分期改变50.7%,放疗管理改变56.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery and 60 presented with recurrent PSA following definitive therapy. Changes in TNM classification of malignant tumors (TNM) stage and radiotherapeutic management after 68Ga-PSMA-11 imaging were compared to results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment naïve patients, a change in TNM stage and radiotheraeutic plan occurred in 26.0% and 44.0% of the cohort respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3% respectively. Conclusion:68Ga-PSMA-11 PET/CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naïve patients as well as in men with recurrent disease or persistent PSA and seems to be very helpful in personalizing radiotherapeutic management to the individual patients' distribution of disease.
引用
- Koerber SA, Will L, Kratochwil C, et al. 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. J Nucl Med. 2018. PMID: 29976697. doi:10.2967/jnumed.118.211086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。